Welcome to CML-IQ. CML-IQ is a free information service offering the latest research news on chronic myelogenous leukemia (CML), tips on living with the disease, and practical advice to help in making decisions.
Forty years ago, researchers identified the acquired genetic defect that drives the white blood cell proliferation that is the hallmark of CML. But it was only at the beginning of the 21st century that researchers were able to develop medications to selectively target this defect. These medications, called TKIs (tyrosine kinase inhibitors), have revolutionized the treatment of CML and are now the cornerstone of CML therapy. But research hasn’t ended there. Countless studies are published every year, contributing to new insights about established treatments and leading to the development of new medications. The hope is that these advances will result in further improvements in the lives of people living with CML.
The mission of CML-IQ is to provide an unbiased online information resource to enable people to gain a greater understanding of the disease, the treatments and the various research avenues being explored. More importantly, CML-IQ provides the context to make the information useful to help people make more informed decisions during the course of their disease.
Funding of CML-IQ is provided through a variety of research initiatives that enable CML healthcare providers and other stakeholders to increase their own understanding of the needs of people whose lives are affected by CML.
If you would like more information on CML-IQ, please email us at info@CML-IQ.com.
Subscribe to CML-IQ
The field of CML is changing daily and people need timely information. Stay in touch by subscribing to the CML-IQ website updates. Subscriptions are free.
CML-IQ is published and produced by:
Lind Publishing Inc.